Weill Consulting Group is a biomedical consulting firm specializing in providing medical and legal consultation to both public and private entities involved in organ transplantation, advanced lung diseases and occupational lung diseases.
For over two decades, our Principal and Founder, Dr. David Weill, has led successful lung transplant programs and advanced lung disease practices. He also has consulted extensively in the oversight of transplant programs, including matters related to the clinical, regulatory, and financial management of transplant centers.
Our Group also is retained to provide expert opinion with regard to a variety of occupational lung diseases, including those that lead to transplantation.
The Weill Consulting Group has an extensive list of clients that includes public and private hospitals, governmental agencies, trade associations, and law firms. They have benefited from Dr. David Weill’s extensive experience, most recently as Director of the Center for Advanced Lung Disease and Director of the Lung and Heart-Lung Transplant Program at Stanford University Medical Center. Dr. Weill’s work has involved site visiting and providing specific recommendations that have led to significant improvements in the transplant programs with whom he has partnered. Our team is committed to providing you with the highest level of medical and scientific expertise whether it is for improving your current transplantation program, starting a new one or dealing with legal issues that may arise.
Dr. David Weill has been in the forefront of developing and running some of the most successful lung transplant programs in the country. He served as Director of the Lung and Heart-Lung Transplant Program at Stanford University Medical Center from 2005-2016. He also developed the Stanford Center for Advanced Lung Disease which provides care for hundreds of patients with cystic fibrosis, interstitial fibrosis, pulmonary hypertension, and emphysema. During this period, he also directed a rebuilding effort of the lung transplant program, producing some of the best outcomes in the country, while increasing the transplant program volume more than three-fold.
In addition to his medical practice, Dr. Weill has testified before the U.S. Congress regarding occupational lung diseases. He has also published extensively in the medical literature regarding lung transplantation, occupational lung disease and advanced lung disease.
He and his wife Jackie recently moved to his hometown of New Orleans with their two daughters.
Dr. Weill was an invited participant in the Collaborative on Lung Transplant Research sponsored by the National Heart Lung and Blood Institute and the American Association of Thoracic Surgery in June of 2017.
The purpose of the meeting was to identify the most important research questions facing the lung transplant community. Dr. Weill made a presentation to the group entitled: Which Candidates Should Receive Single vs Bilateral Lung Transplants?
Dr. Weill’s involvement in the transplantation field includes:
David Weill, MD, discusses cystic fibrosis (CF) in adults, and treatment resources available at Stanford Hospital’s Adult Cystic Fibrosis Center, part of the Center for Advanced Lung Disease.10-year-old girl gets adult lung transplant
Sarah Murnaghan, a 10 year old girl with cystic fibrosis, is getting a new set of lungs after her family fought to have her prioritized for adult organs. Brooke Baldwin talks to Dr. David Weill about the risks and complications of putting adult lungs into a child’s body.
I left Stanford after many years of successfully directing the Lung Transplant Program in order to address an important deficiency in transplant care – the lack of comprehensive quality information about transplant program performance.
In the United States, there are hundreds of transplant programs performing thousands of solid organ transplants per year. Based on my own experiencing directing programs and evaluating them for public and private entities, I have seen that the quality of the programs varies considerably. This variability is usually not apparent to patients.
Develop a scientifically reliable way to evaluate transplant program quality by using a variety of metrics that will be proposed and tested by experts in each of the four solid organ transplants (heart, liver, kidney, and lung). In order to achieve this mission, I have set up a non-profit entity called the Coalition for Transplant Program Evaluation (CTPE).
TGH, USF Health Tap Dr. David Weill to Lead New Institute for Advanced Organ Disease and Transplantation
Tampa, FL ( June 10, 2017 ) – Tampa General Hospital and the USF Health Morsani College of Medicine are creating a new model for medical care. Noted transplant physician Dr. David Weill has been named director of the new Institute for Advanced Organ Disease and Transplantation, which will bring together the four solid organ transplant programs under singular leadership.
The institute will serve patients in need of solid organ transplants or who suffer complex medical conditions as a result of advanced organ disease of the heart, lungs, liver, pancreas, and kidneys at Tampa General, already one of the nation’s busiest transplant centers, and at USF Health’s South Tampa Center for Advanced Medical Care.
“Dr. Weill’s clinical expertise and his vision for how to improve outcomes and enhance quality of care are aligned with what we’re already doing here at TGH,” said Dr. Sally Houston, chief medical officer at Tampa General. “Dr. Weill is working with our seasoned team of physicians to create a new model that will better coordinate clinical care and enhance the patient experience at all stages of organ failure.” Dr. Charles J. Lockwood, senior vice president for USF Health and dean of the USF Health Morsani College of Medicine, says the institute will offer high-quality, integrated care with cutting-edge clinical research designed to benefit a wide range of patients.
“In each of our transplant areas, this academic-affiliated institute will enable us to create pathways of subspecialty care to help patients with complex disorders delay or even avoid a transplant; to seamlessly transition to a transplant when needed, while minimizing postsurgical complications; and to maximize quality of life,” Dr. Lockwood said.
Dr. Weill has big plans for the institute. “No matter how good outcomes are, we can always do better. We’re going after the most experienced physicians and we will dig deep with our research. This is critical, because it gives you better ways to improve patient care, and we’ll be laser-focused on training the next generation of physicians for our rapidly-growing transplant program.”
Weill says the new Institute in Tampa will also work to increase clinical trials, publish more research results, and compete for more research grants. Patients will have the opportunity to participate in these trials and know that they have access to the latest advances in medical treatment. The Institute will also offer specialized fellowships, offering some of the nation’s top young doctors the opportunity to get top-level training in the complex care that patients with advanced organ disease need.
“With the vision and leadership of Dr. Weill, our partnership will dramatically advance the national visibility of the already outstanding transplant service at Tampa General Hospital by increasing academic research productivity,” Lockwood said. Weill is the former director of the Center for Advanced Lung Disease and the Lung and Heart-Lung Transplant Program at Stanford University Medical Center. He is also past chair of the Pulmonary Transplantation Council of the International Society of Heart and Lung Transplantation. He served ten years on the editorial board of the Journal of Heart and Lung Transplantation and in several capacities for the United Network for Organ Sharing, including as a member of the Thoracic Committee, a member of the National Lung Review Board, and a member of the Membership and Professional Standards Committee.
Weill received his BA from Tulane University and his MD from Tulane University Medical School. He completed his residency at Parkland Hospital, University of Texas – Southwestern and a fellowship in Pulmonary and Critical Care Medicine and Lung Transplantation at the University of Colorado at Denver and Health Sciences Center.
Dr. Weill is the Chairman of an exciting international conference being held this fall. The Monticello Conference on Elongated Mineral Particles: An Assessment of Health Effects, Definitions, and Research Priorities will be held in Charlottesville, Virginia on October 17 - 20, 2017. The purpose of the Monticello Conference is to gather thought leaders to elucidate the mechanisms by which various inhalations either do or do not have the potential to elevate risk for developing asbestos related diseases, most notably mesothelioma. Through a series of scientific presentations, invited scientists will have the opportunity to discuss the best evidence in various disciplines including toxicology, lung biology, analytical techniques, mineralogy, risk assessment, and epidemiology.
Link to the meeting website: